步长制药：全资子公司获得磷酸奥司他韦胶囊药品注册证书

Core Viewpoint - The approval of the drug registration certificate for Oseltamivir Phosphate Capsules by the National Medical Products Administration is a significant milestone for the company, enhancing its product portfolio and production capacity, which is expected to positively impact future operations [1] Group 1 - The company announced that its wholly-owned subsidiary, Shaanxi Buchang High-tech Pharmaceutical Co., Ltd., has received the drug registration certificate for Oseltamivir Phosphate Capsules [1] - Oseltamivir Phosphate Capsules are primarily used for the treatment of influenza A and B in adults and children aged one year and older, as well as for prevention in adults and adolescents aged 13 years and older [1] - The registration of this drug is beneficial for the company to optimize its product structure and maintain stable production capacity to meet market demand [1]